Strong Sales Performance
Sales grew 9% as reported and 8% in constant currency, with instruments growing mid-single digits and recurring revenue up 11%. Waters Division performed well across Americas, Europe, and Asia.
Significant Growth in Pharma Segment
Pharma segment grew 11%, with strong instrument replacement activity and product adoption among large pharma and CDMO customers.
Increased Guidance for Fiscal Year 2025
Full year 2025 constant currency sales growth guidance raised to 5.5% to 7.5%, and non-GAAP EPS guidance increased to $12.95 to $13.05.
Expansion in High-Growth Areas
E-commerce adoption above 40% of chemistry revenue, service plan attachment increased by 200 basis points, and CDMO penetration at 27% of pharma revenue.
Successful Product Launches
Alliance iS sales grew 300% year-over-year, Xevo TQ Absolute platforms grew 40%, and MaxPeak premier columns saw over 30% growth.
Strong Performance in China
Asia grew 14%, with double-digit growth in China. Strong performance across all end markets, particularly in CDMOs and battery testing.